🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Top 7 Research Reports For July 13, 2016

Published 07/13/2016, 01:00 AM
Updated 07/09/2023, 06:31 AM
COP
-
COR
-
CB
-
MPC
-

Wednesday, July 13, 2016

Today's must-read reports are for Bristol-Myers (BMY), ConocoPhillips (NYSE:COP) (COP) and eBay (EBAY).

Bristol-Myers shares are up +11% year-to-date, with this Zacks Rank # 2 (Buy) rated stock getting a boost when its cancer drug, Opdivo, became the first PD-1 immune checkpoint inhibitor to gain regulatory approval anywhere in the world. The analyst likes the company’s higher guidance for 2016 and its concerted efforts to develop its pipeline are also encouraging. (You can read the full research report on BMY here.)

Zacks Rank # 2 (Buy) rated ConocoPhillips shares have been laggards lately, but the analyst likes ConocoPhillips’ greater focus on North America, Australia and Asia which is expected to improve its risk profile. Additionally, ConocoPhillips’ initiatives towards liquids-rich plays are starting to bear fruit buoyed by the Eagle Ford, Bakken and Permian plays. (You can read the full research report on COP here.)

Despite lingering in the red year-to-date, shares of eBay have gained more than 5% over the last one month. The analyst likes the Zacks Rank # 2 (Buy) rated stock’s opportunities in the fast-growing mobile space, international expansion and a strong balance sheet. The company's concerted efforts to squeeze additional costs out of its operations hold the promise of a boost to margins in the coming quarters. (You can read the full research report on EBAY here.)

Other noteworthy reports we are featuring today include Pepsi (PEP), Viacom (VIAB) and Suncor Energy (SU).

You can find all of today's stock research reports here.

Sheraz Mian

Director of Research

Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles include Earnings Trends and Earnings Preview. He also provides weekly commentary to Zacks Premiumsubscribers and manages the Zacks Focus Listand Top 10portfolios. If you want an email notification each time Sheraz publishes a new article, please click here

Featured Reports

Pepsi (PEP) Beats, Higher EPS Outlook Encouraging

Pepsi raised its full year earnings growth target based on strong performance in the first half and a favorable outlook, which encourages the Zacks analyst.

Annaly (NLY) to Benefit from Hatteras Acquisition

The Zacks analyst thinks Annaly's acquisition of Hatteras is likely to boost its status in the REIT space.

Franklin's (BEN) June AUM Declines as Equity Assets Drop

The covering analyst thinks that though Brexit-related volatility affected assets under management in June, its solid business model and strong distribution platform support growth prospects.

Chubb (NYSE:CB) Expects Q2 Catastrophe Loss of $315 Million

Chubb expects to incur catastrophe loss of $315 million ($390 million pre-tax) net of reinsurance and including reinstatement premiums in the second quarter.

Key Products and Robust Pipeline to Boost BioMarin (BMRN)

Solid performance of key products like Vimizim and Kuvan will drive BioMarin's top line, according to the Zacks analyst. also has a promising pipeline.

Illinois Tool (ITW) Eyes Growth Despite Stiff Competition

Illinois expects its financials to be boosted by Enterprise Strategy and other initiatives. However, the Zacks analyst feels unfavorable currency movements and intense competition might hurt results.

T. Rowe Price (TROW) on Growth Track, Cost Pressure Lingers

The Zacks analyst thinks despite pressure on expenses, the company stands to benefit from a diverse business model, launch of new funds and substantial liquidity.

New Upgrades

Align Technology (ALGN) to Gain from Solid Invisalign Growth

The Zacks Analyst believes Align's expected incremental investments in Invisalign during 2H16 to successfully boost its business in 2016. Recent adoption of digital scanners also buoys optimism.

Suncor Energy's (SU) Prospects Improve on Higher Syncrude Stake

The covering analyst thinks Suncor's prospects have improved after the company significantly increased its stake in the Syncrude oilsands project. Oil recovery also acts as a catalyst.

AmerisourceBergen (NYSE:ABC) To Benefit From Acquisitions, Deals

AmerisourceBergen should benefit from strategic acquisitions which have diversified its target markets and should help combat the slowdown in generics, according to the Zacks analyst.

New Downgrades

Marathon Petroleum (NYSE:MPC) Downgraded on Narrowing Spread

The Zacks analyst believes that following a prolonged period of high differentials, crack spreads are set to weaken, which will lead to a decline in earnings and cash flows for MPC.

Viacom (VIAB) Corporate Battle, Prospects Worry Investors

The covering analyst thinks Viacom remains embroiled in corporate issues and the company's future prospects and a positive turnaround remain doubtful.

Twitter (TWTR) Signs Several Streaming Deals to Attract Users

Twitter's multiple efforts at boosting the user base including live streaming deals with the likes of NFL are impressive but questions remain about whether they will yield results.



VIACOM INC-B (VIAB): Free Stock Analysis Report

SUNCOR ENERGY (SU): Free Stock Analysis Report

PEPSICO INC (PEP): Free Stock Analysis Report

EBAY INC (EBAY): Free Stock Analysis Report

CONOCOPHILLIPS (COP): Free Stock Analysis Report

BRISTOL-MYERS (BMY): Free Stock Analysis Report

Original post

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.